Related Experiment Video
Updated: Apr 3, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
The Cardiac Genetics Clinic: a model for multidisciplinary genomic medicine
Dominica Zentner1, Tina N Thompson2, Paul A James2
1Royal Melbourne Hospital, Melbourne, VIC dominica.zentner@mh.org.au.
Insights
Genetic testing for cardiac conditions identified pathogenic mutations in 15.3% of patients at a specialized clinic. The Cardiac Genetics Clinic (CGC) provides crucial diagnostic and risk management services for inherited cardiac diseases.
Area of Science:
- Cardiovascular Medicine
- Medical Genetics
- Clinical Diagnostics
Background:
- Multidisciplinary Cardiac Genetics Clinics (CGC) are essential for diagnosing and managing inherited cardiac conditions.
- Understanding patient demographics and the utility of genetic testing is crucial for service optimization.
Purpose of the Study:
- To characterize patient profiles, clinical procedures, and genetic testing uptake at the Royal Melbourne Hospital's CGC over its initial six years.
- To evaluate the diagnostic yield of genetic testing in a diverse cohort with inherited cardiac diseases.
Main Methods:
- A retrospective database review of 1170 individuals attending the CGC between July 2007 and July 2013.
- Patients were categorized by cardiac diagnosis, and data on clinic visits and genetic testing incidence were analyzed.
Main Results:
- 32.6% of individuals (381/1170) underwent genetic testing, with pathogenic mutations identified in 47.6% of these tests.
- The most common diagnostic categories were cardiomyopathy, aortopathy, arrhythmia disorders, and sudden cardiac death/family history.
- A pathogenic mutation was identified in 15.3% of the total patient population.
Conclusions:
- The CGC plays a vital role in diagnosing and managing patients with genetic cardiac conditions.
- Clinical practice evolved from candidate gene testing to broader next-generation sequencing panels, potentially increasing mutation detection.
- The clinic provides essential diagnostic clarity and risk management plans for individuals and families affected by inherited cardiac diseases.
Objectives:
To describe patient characteristics, standard operating procedure, and uptake of genetic testing at the multidisciplinary Cardiac Genetics Clinic (CGC) at the Royal Melbourne Hospital during its first 6 years.
Design:
Database exploration of referral diagnoses, sex, number of clinic visits and incidence of genetic testing in a population of individuals attending the CGC.
Setting:
Tertiary referral hospital (Royal Melbourne Hospital) providing cardiac genetics services to the state of Victoria.
Participants:
All individuals initially attending the clinic between July 2007 and July 2013, either as the proband or as an at-risk family member.
Main Outcome Measures:
Classification of patients into diagnostic categories, number of probands and at-risk relatives assessed, incidence and outcomes of genetic testing.
Results:
1170 individuals were seen for the first time over the 6-year period; 57.5% made only one visit. The median age was 39 years. Most were encompassed within four broad diagnostic categories: cardiomyopathy (315 patients), aortopathy (303 patients), arrhythmia disorders (203 patients) and resuscitated cardiac arrest and/or family history of sudden cardiac death (341 patients); eight patients had "other" diagnoses. Genetic testing (mutation detection or predictive testing) was undertaken in 381 individuals (32.6%), and a pathogenic mutation was identified in 47.6% of tests, representing 15.3% of the total population.
Conclusion:
The CGC fulfils an important role in assisting clinicians and patients by reviewing genetic cardiac diagnoses. Clinical practice during the study period moved from a selected candidate gene approach to broader gene panel-based testing. This move to next-generation sequencing may increase the detection of mutations and variants of unknown significance. A major contribution by the clinic to the care of these individuals and their families is the provision (or negating) of a diagnosis, and of a plan for managing risks of predictable cardiac disease.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Pharmacogenetics and Pharmacogenomics: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...

